BRPI0412989A - combinação farmacêutica útil para mobilização de célula-tronco - Google Patents

combinação farmacêutica útil para mobilização de célula-tronco

Info

Publication number
BRPI0412989A
BRPI0412989A BRPI0412989-0A BRPI0412989A BRPI0412989A BR PI0412989 A BRPI0412989 A BR PI0412989A BR PI0412989 A BRPI0412989 A BR PI0412989A BR PI0412989 A BRPI0412989 A BR PI0412989A
Authority
BR
Brazil
Prior art keywords
stem cell
pharmaceutical combination
cell mobilization
combination useful
useful
Prior art date
Application number
BRPI0412989-0A
Other languages
English (en)
Inventor
Alessandro Massimo Gianni
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of BRPI0412989A publication Critical patent/BRPI0412989A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMBINAçãO FARMACêUTICA úTIL PARA MOBILIZAçãO DE CéLULA-TRONCO". A presente invenção refere-se a preparação farmacêutica combinada contendo G-CSF e PIGF como as substâncias ativas é útil na mobilização de células-tronco sangüíneas em um paciente ou indivíduo com necessidade das mesmas.
BRPI0412989-0A 2003-07-29 2004-07-23 combinação farmacêutica útil para mobilização de célula-tronco BRPI0412989A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03017174 2003-07-29
PCT/EP2004/008245 WO2005014023A1 (en) 2003-07-29 2004-07-23 Pharmaceutical combination of g-csf and plgf useful for blood stem cell

Publications (1)

Publication Number Publication Date
BRPI0412989A true BRPI0412989A (pt) 2006-10-03

Family

ID=34130041

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412989-0A BRPI0412989A (pt) 2003-07-29 2004-07-23 combinação farmacêutica útil para mobilização de célula-tronco

Country Status (21)

Country Link
US (1) US20070036747A1 (pt)
EP (1) EP1660115B1 (pt)
JP (1) JP4855253B2 (pt)
KR (1) KR101192136B1 (pt)
CN (1) CN100534528C (pt)
AT (1) ATE513555T1 (pt)
AU (1) AU2004262909B2 (pt)
BR (1) BRPI0412989A (pt)
CA (1) CA2526244C (pt)
DK (1) DK1660115T3 (pt)
ES (1) ES2369487T3 (pt)
IL (1) IL173369A (pt)
MX (1) MXPA06000017A (pt)
NO (1) NO20060955L (pt)
NZ (1) NZ543612A (pt)
PL (1) PL1660115T3 (pt)
PT (1) PT1660115E (pt)
RU (1) RU2351357C2 (pt)
SI (1) SI1660115T1 (pt)
WO (1) WO2005014023A1 (pt)
ZA (1) ZA200509361B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2206719E (pt) 2005-03-02 2015-02-05 Univ Maryland Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
BR112012002797A2 (pt) 2009-08-07 2019-09-24 Tokai Pharmaceuticals Inc tratamento de câncer de próstata
KR20160023638A (ko) 2013-02-28 2016-03-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 이동하기 위한 방법 및 조성물
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
CN114891746A (zh) * 2021-12-21 2022-08-12 青岛今墨堂生物技术有限公司 一种犬全血造血干细胞的制备方法
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7105168B1 (en) * 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
EP1147777A1 (en) * 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
KR20030034177A (ko) * 2000-09-13 2003-05-01 쥬가이 세이야쿠 가부시키가이샤 허혈성 질환 치료제
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
EP1594527A2 (en) * 2003-02-04 2005-11-16 Ludwig Institute For Cancer Research Vegf-b and pdgf modulation of stem cells

Also Published As

Publication number Publication date
MXPA06000017A (es) 2006-03-21
JP2007500157A (ja) 2007-01-11
ZA200509361B (en) 2007-03-28
RU2006106228A (ru) 2007-09-10
NZ543612A (en) 2008-03-28
KR20060079753A (ko) 2006-07-06
PL1660115T3 (pl) 2011-11-30
CN1826134A (zh) 2006-08-30
NO20060955L (no) 2006-02-27
DK1660115T3 (da) 2011-10-10
IL173369A (en) 2010-12-30
ES2369487T3 (es) 2011-12-01
SI1660115T1 (sl) 2011-10-28
EP1660115A1 (en) 2006-05-31
EP1660115B1 (en) 2011-06-22
JP4855253B2 (ja) 2012-01-18
AU2004262909A1 (en) 2005-02-17
RU2351357C2 (ru) 2009-04-10
CA2526244A1 (en) 2005-02-17
WO2005014023A1 (en) 2005-02-17
KR101192136B1 (ko) 2012-10-16
PT1660115E (pt) 2011-08-24
CN100534528C (zh) 2009-09-02
CA2526244C (en) 2012-03-20
AU2004262909B2 (en) 2010-07-01
US20070036747A1 (en) 2007-02-15
ATE513555T1 (de) 2011-07-15
IL173369A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
BRPI0707612B8 (pt) vaso lacrado e formulações líquidas contidas no mesmo
NO20060955L (no) Farmasoytisk sammensetning som er nyttig til stamcellemobilisering
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
NO20064584L (no) Tetrahydropyridoindolderivater
MXPA05012319A (es) Suministro de compuestos con celulas sanguineas rehidratadas.
WO2005025615A3 (en) FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
PA8594801A1 (es) Formulaciones farmaceuticas liquidas de palanosetron
EA200602137A1 (ru) Гидрогелевые препараты интерферона
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
BRPI0512189A (pt) composições e métodos para cuidados com os cabelos
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita' antiossidante.
DE602004030564D1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7-dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
SE0300457D0 (sv) Novel compounds
FR2883184B1 (fr) Composition de spirulines riche en principes actifs, procede d'obtention et utilisation
WO2004087876A3 (en) Use of red blood cells to facilitate cell activation
WO2004087117A3 (de) Verwendung von cyclischen aketalen/ketalen zur verbesserten penetration von wirkstoffen in zellen und organen
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
NL1022442C2 (nl) Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.
WO2008107785A3 (en) Composition containing autologous mononuclear cells and scaffold and its use in the preparation of a surgical medicament

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DOMPE' S.P.A. (IT)

Free format text: TRANSFERIDO POR FUSAO DE: DOMPE PHA.R.MA S.P.A.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.